Insulet (Nasdaq:PODD) announced today that the FDA granted 510(k) clearance for its Omnipod 5 App for iPhone. Clearance makes Insulet the only company offering a tubeless, automated insulin delivery (AID) system with full control from a compatible Android and iOS smartphone. The company first launched the system, compatible with Android devices, in August 2022. Insulet […]
Technology
The challenges Insulet overcame to deliver the Omnipod 5 automated insulin delivery system
Insulet (Nasdaq:PODD) had to clear a series of hurdles to bring the Omnipod 5 automated insulin delivery system to those who need it. Speaking at DeviceTalks West in Santa Clara, California on Oct. 18, Mark Field, Insulet’s CTO, explained the trials and tribulations. He presented in a session titled “Overcoming Challenges to Develop the Omnipod […]
How automated insulin delivery integration drives Dexcom CGM forward
Dexcom (Nasdaq:DXCM) is a company known as one of the market leaders in continuous glucose monitoring (CGM) technology. CGMs are a key system for people with diabetes to manage their condition. But, Dexcom has worked to ensure that its CGM technology goes beyond its standalone capabilities. The Dexcom G6, the company’s previous-generation CGM, integrates with […]
How the new Medtronic CGM-insulin pen combo simplifies diabetes management
Medtronic (NYSE:MDT) named its next-generation “Simplera” continuous glucose monitor (CGM) as a nod to its simplicity. The company, which just initiated the system’s launch in Europe following CE mark approval, is exceedingly optimistic about the technology. Medtronic’s all-in-one, disposable CGM features a simple, two-step insertion process for people with diabetes using multiple daily injections (MDI). Its […]
Ypsomed: closed-loop insulin dosing improves health of pregnant women with type 1 diabetes
Ypsomed today announced clinical study data demonstrating the benefits of its hybrid closed-loop insulin delivery system for pregnant women. Pregnant women with type 1 diabetes and their babies benefitted from the automated insulin delivery system based on the CamDiab CamAPS FX algorithm. The New England Journal of Medicine published these outcomes from Ypsomed’s AiDAPT clinical study. Ypsomed says […]
Abbott updates FreeStyle Libre 2 app with silent alarm mode
Abbott (NYSE:ABT) announced today that it released a new FreeStyle Libre 2 app version with fully customizable alarms. The updated app release for the Abbott continuous glucose monitor (CGM) system — version 2.7.5 — features silent mode. This enables people with diabetes to use their CGM with less interruptions throughout the day. Silent mode delivers […]
Novo Nordisk acquires all shares of drug delivery device maker Biocorp
Novo Nordisk today officially acquired 100% of the shares of Biocorp, the France-based drug delivery device maker’s CEO announced. Biocorp designs, develops and manufactures drug delivery systems and medical devices. Its offerings include Mallya, a Bluetooth-enabled smart add-on device for pen injectors. The Mallya smart sensor attaches directly to insulin pen injectors to make them […]
Medtronic warns on previous software MiniMed 780G in Germany
Medtronic (NYSE:MDT) issued an urgent field safety notice in Germany to warn of a potential issue with its MiniMed 780G system. MiniMed 780G, Medtronic’s next-generation automated insulin delivery system, has been available in Europe since earning CE mark in mid-2020. In March 2021, the company first communicated that its pumps with software version 6.5 could […]
New data shows consistency of Medtronic MiniMed 780G in different demos, cultures
Medtronic (NYSE:MDT) today announced real-world data demonstrating the global consistency of its MiniMed 780G automated insulin delivery system. The data, according to Medtronic, demonstrates that using the system allows people with diabetes to meet or exceed internationally recommended targets regardless of location. The medtech giant says a barrier to automated insulin delivery (AID) adoption and […]
Dexcom launches next-gen G7 CGM in Canada
Dexcom (Nasdaq:DXCM) today announced the commercial launch of its next-generation G7 continuous glucose monitor (CGM) in Canada. The San Diego-based company expects to make its latest CGM technology available to Canadians on Oct. 10, 2023. It covers people with all types of diabetes aged two and older, including those who are pregnant, in the country. […]